Fellowship Opportunities
Advanced Developmental Therapeutics Training Program (ADTTP)
The Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) is seeking candidates for the position of Clinical Fellow/Senior Clinical Fellow in the DCTD Clinical Oncology Advanced Developmental Therapeutics Training Program (ADTTP). This program provides medical oncologists and board eligible medical oncologists advanced training in state-of-the-science principles and technologies of developmental therapeutics, utilizing the unique resources available within NCI. The successful candidate(s) will participate in translational research conducted in the NCI Developmental Therapeutics Clinic (DTC) at the NIH Clinical Center in Bethesda, Maryland. The ADTTP fellow will participate in the development process from conceptualization of an idea, presenting the idea in written and verbal form to reviewing committees (CTEP, IRB), and ultimately leading the trial under the mentorship of the DTC faculty.
The ADTTP is approved by the Graduate Medical Education Committee (GMEC) at the NIH as a non-accredited/non-standard subspecialty training in Hematology and Oncology/Investigational Cancer Therapeutics.
Who Is Eligible To Apply?
Candidates must meet all of the following requirements
- M.D. or an equivalent degree with a license to practice medicine in the United States
- Completion of subspecialty training in adult medical oncology at a U.S. accredited institution
- Board certification or eligibility in medical oncology
A full federal package of benefits (including retirement, leave, health and life insurance, and a 401K-equivalent savings plan, etc.) is available. This is a time-limited federal appointment not-to-exceed three years because there is no assurance of a tenure-track or permanent position with NCI or NIH upon completion of the program. Salary will be commensurate with training and experience.
How To Apply
To apply for this position, please submit your curriculum vitae, three letters of recommendation, preferably one from the medical oncology training program director or supervisor of your last professional position, and a personal statement of research goals to Monika Sarna, DCTD Adminstrative Officer, at msarna@mail.nih.gov.
What Is Special About The ADTTP?
Increased numbers of novel therapeutic agents and the progressively greater complexity of early-phase clinical trials have led to a need for more physicians with special skills in drug development. The ADTTP will provide an excellent opportunity to refine trainee skills in clinical investigation, including novel strategies for trial design and methodology; protocol development, execution, and monitoring; conformity with ethical standards; and formulation of attainable and pertinent laboratory correlates.
The trainee(s) will spend 40 to 60 percent of their time in clinical investigations involving inpatients and outpatients at the NIH Clinical Center, including a minimum of 1.5 days in DTC clinic activities. In addition, the trainee(s) will spend up to 40 percent of their time in DCTD’s Cancer Therapy Evaluation Program (CTEP). The CTEP component of the training will broaden the trainee’s knowledge of new drug development by providing a unique opportunity to learn the principles and concepts of agent prioritization, drug development strategies, protocol development and review, investigational new drug (IND) application requirements, and adverse event assessment and reporting.